IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
- 1 May 1999
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 52 (8), 1701
- https://doi.org/10.1212/wnl.52.8.1701
Abstract
Article abstract Current treatments for anti-GM1 ganglioside or antimyelin-associated glycoprotein (anti-MAG) antibody-associated polyneuropathies are toxic or very costly. In this preliminary study the authors treated five patients with neuropathy and immunoglobulin M antibodies to GM1 ganglioside or MAG by depleting B cells using Rituximab—a monoclonal antibody directed against the B-cell surface membrane marker CD20. Within 3 to 6 months after treatment, all five patients had improved function, significantly increased quantitative strength measurements, and reduced titers of serum autoantibodies.Keywords
This publication has 5 references indexed in Scilit:
- Anti-MAG antibody-associated polyneuropathiesNeurology, 1995
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.The EMBO Journal, 1988
- The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.The Journal of Immunology, 1985
- Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiationBlood, 1984